Asthma across the ages: Knowledge gaps in childhood asthma
详细信息 查看全文
- 作者：Stanley J. Szefler ; James F. Chmiel ; Anne M. Fitzpatrick ; George Giacoia ; Thomas P. Green ; Daniel J. Jackson ; Heber C. Nielsen ; W ; a Phipatanakul ; Hengameh H. Raissy
- 关键词：Asthma ; asthma natural history ; asthma progression ; asthma biomarkers ; childhood asthma ; asthma pharmacotherapy
- 刊名：Journal of Allergy and Clinical Immunology
- 出版年：January, 2014
- 年：2014
- 卷：133
- 期：1
- 页码：3-13
- 全文大小：761 K
文摘
The Eunice Kennedy Shriver National Institute of Child Health and Human Development convened an Asthma Group in response to the Best Pharmaceuticals for Children Act. The overall goal of the Best Pharmaceuticals for Children Act Program is to improve pediatric therapeutics through preclinical and clinical drug trials that lead to drug-labeling changes. Although significant advances have been made in the understanding and management of asthma in adults with appropriately labeled medications, less information is available on the management of asthma in children. Indeed, many medications are inadequately labeled for use in children. In general, the younger the child, the less information there is available to guide clinicians. Because asthma often begins in early childhood, it is incumbent on us to continue to address the primary questions raised in this review and carefully evaluate the medications used to manage asthma in children. Meanwhile, continued efforts should be made in defining effective strategies that reduce the risk of exacerbations. If the areas of defined need are addressed in the coming years, namely prevention of exacerbations and progression of disease, as well as primary intervention, we will see continuing reduction in asthma mortality and morbidity along with improved quality of life聽for聽children with asthma.